Clene Inc. (CLNNW)
2025-06-30 | ||||
|---|---|---|---|---|
| Total revenue | 27 | |||
| Research and development | 3,514 | |||
| General and administrative | 2,377 | |||
| Cost of revenue | - | |||
| Total operating expenses | 5,891 | |||
| Loss from operations | -5,864 | |||
| Change in fair value of derivative liabilities | -439 | |||
| Interest income | 62 | |||
| Interest expense | 679 | |||
| Research and development tax credits and unrestricted grants | 16 | |||
| Change in fair value of common stock warrant liabilities | 515 | |||
| Change in fair value of initial stockholders contingent earn-out liability | - | |||
| Change in fair value of clene nanomedicine contingent earn-out liability | - | |||
| Total other income (expense), net | -1,555 | |||
| Net loss before income taxes | -7,419 | |||
| Income tax expense | - | |||
| Net loss | -7,419 | |||
| Unrealized loss on available-for-sale securities | - | |||
| Foreign currency translation adjustments | 63 | |||
| Total other comprehensive income (loss) | 63 | |||
| Comprehensive loss | -7,356 | |||
| Net loss per share basic and diluted (in dollars per share) | -0.78 | |||
| Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 9,523,592 | |||